NVCT Stock Overview
A biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nuvectis Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.55 |
| 52 Week High | US$12.10 |
| 52 Week Low | US$4.44 |
| Beta | 0.17 |
| 1 Month Change | 25.48% |
| 3 Month Change | -16.45% |
| 1 Year Change | -14.49% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 101.54% |
Recent News & Updates
Recent updates
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans
Oct 20
We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully
Jun 26Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
Jan 06Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
Oct 03We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
Jan 31Nuvectis Pharma forms scientific advisory board for research and development of drugs
Sep 28Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04
Aug 05Nuvectis Pharma declines 13%, announces $15.9M private placement
Jul 27We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
May 04Shareholder Returns
| NVCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 19.3% | 3.6% | 1.8% |
| 1Y | -14.5% | -3.7% | 24.9% |
Return vs Industry: NVCT underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: NVCT underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| NVCT volatility | |
|---|---|
| NVCT Average Weekly Movement | 20.4% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NVCT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NVCT's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 13 | Ron Bentsur | www.nuvectis.com |
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company’s lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases.
Nuvectis Pharma, Inc. Fundamentals Summary
| NVCT fundamental statistics | |
|---|---|
| Market cap | US$126.55m |
| Earnings (TTM) | -US$19.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.5x
P/E RatioIs NVCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVCT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.37m |
| Earnings | -US$19.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NVCT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/26 04:58 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nuvectis Pharma, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Aydin Huseynov | Ladenburg Thalmann & Company |
| Jonathan Aschoff | Roth Capital Partners |